Role of Striatal A2A Receptor Subpopulations in Neurological Disorders

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Unknown venue

• Publication date

  2013-11-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1007/978-1-4614-3903-5_9
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Pharmacological evidence for different populations of postsynaptic adenosine A2A receptors in the rat striatum.

  2011cited by this paper
• Adenosine 2A receptor availability in dyskinetic and nondyskinetic patients with Parkinson disease

  2011cited by this paper
• Functional changes in postsynaptic adenosine A(2A) receptors during early stages of a rat model of Huntington disease.

  2011cited by this paper
• The Distinct Role of Medium Spiny Neurons and Cholinergic Interneurons in the D2/A2A Receptor Interaction in the Striatum: Implications for Parkinson's Disease

  2011cited by this paper
• Pre‐synaptic adenosine A2A receptors control cannabinoid CB1 receptor‐mediated inhibition of striatal glutamatergic neurotransmission

  2011cited by this paper
• Striatal Pre- and Postsynaptic Profile of Adenosine A2A Receptor Antagonists

  2011cited by this paper
• Reinforcing and neurochemical effects of cannabinoid CB1 receptor agonists, but not cocaine, are altered by an adenosine A2A receptor antagonist

  2011cited by this paper
• THEMED ISSUE: CANNABINOIDS REVIEW Adenosine–cannabinoid receptor interactions. Implications for striatal functionbph_723 443..453

  2010cited by this paper
• An Open-Label, Positron Emission Tomography Study to Assess Adenosine A2A Brain Receptor Occupancy of Vipadenant (BIIB014) at Steady-State Levels in Healthy Male Volunteers

  2010cited by this paper
• A2A adenosine receptor overexpression and functionality, as well as TNF‐α levels, correlate with motor symptoms in Parkinson's disease

  2010cited by this paper
• Istradefylline as monotherapy for Parkinson disease: results of the 6002-US-051 trial.

  2010cited by this paper
• A long-term study of istradefylline in subjects with fluctuating Parkinson's disease.

  2010cited by this paper
• Interactions between Intracellular Domains as Key Determinants of the Quaternary Structure and Function of Receptor Heteromers*

  2010cited by this paper
• Clinical efficacy of istradefylline (KW‐6002) in Parkinson's disease: A randomized, controlled study

  2010cited by this paper
• Age at onset in Huntington’s disease: replication study on the associations of ADORA2A, HAP1 and OGG1

  2010cited by this paper
• Endocannabinoid Signaling Mediates Psychomotor Activation by Adenosine A2A Antagonists

  2010cited by this paper
• Competitive regulation of synaptic Ca influx by D2 dopamine and A2A adenosine receptors

  2010cited by this paper
• Up-regulation of striatal adenosine A(2A) receptors with iron deficiency in rats: effects on locomotion and cortico-striatal neurotransmission.

  2010cited by this paper
• Diminished iron concentrations increase adenosine A(2A) receptor levels in mouse striatum and cultured human neuroblastoma cells.

  2009cited by this paper
• Building a new conceptual framework for receptor heteromers.

  2009cited by this paper
• Key Modulatory Role of Presynaptic Adenosine A2A Receptors in Cortical Neurotransmission to the Striatal Direct Pathway

  2009cited by this paper
• Adenosine A2A receptors enable the synaptic effects of cannabinoid CB1 receptors in the rodent striatum

  2009cited by this paper
• Dopamine D2 and Adenosine A2A Receptors Regulate NMDA-Mediated Excitation in Accumbens Neurons Through A2A–D2 Receptor Heteromerization

  2009cited by this paper
• Altered dopaminergic profile in the putamen and substantia nigra in restless leg syndrome.

  2009cited by this paper
• Metabotropic glutamate type 5, dopamine D2 and adenosine A2a receptors form higher‐order oligomers in living cells

  2009cited by this paper
• A genetic variation in the ADORA2A gene modifies age at onset in Huntington's disease.

  2009cited by this paper
• Detection of heteromerization of more than two proteins by sequential BRET-FRET

  2008cited by this paper
• Reciprocal Regulation of Dopamine D1 and D3 Receptor Function and Trafficking by Heterodimerization

  2008cited by this paper
• An update on adenosine A2A-dopamine D2 receptor interactions: implications for the function of G protein-coupled receptors.

  2008cited by this paper
• Dopamine D2 receptor expression is altered by changes in cellular iron levels in PC12 cells and rat brain tissue.

  2008cited by this paper
• Adenosine A2A receptor antagonist istradefylline (KW‐6002) reduces “off” time in Parkinson's disease: A double‐blind, randomized, multicenter clinical trial (6002‐US‐005)

  2008cited by this paper
• A Critical Role of the Adenosine A2A Receptor in Extrastriatal Neurons in Modulating Psychomotor Activity as Revealed by Opposite Phenotypes of Striatum and Forebrain A2A Receptor Knock-Outs

  2008cited by this paper
• Striatal Adenosine A2A and Cannabinoid CB1 Receptors Form Functional Heteromeric Complexes that Mediate the Motor Effects of Cannabinoids

  2007cited by this paper
• Functional relevance of neurotransmitter receptor heteromers in the central nervous system.

  2007cited by this paper
• Circuits and circuit disorders of the basal ganglia.

  2007cited by this paper
• Functions, dysfunctions and possible therapeutic relevance of adenosine A2A receptors in Huntington's disease.

  2007cited by this paper
• Adenosine A2A receptors and basal ganglia physiology.

  2007cited by this paper
• Early and transient alteration of adenosine A2A receptor signaling in a mouse model of Huntington disease.

  2006cited by this paper
• Behavioral abnormalities precede neuropathological markers in rats transgenic for Huntington's disease.

  2006cited by this paper
• Regulation of phosphorylation of the GluR1 AMPA receptor by dopamine D2 receptors

  2006cited by this paper
• Iron deficiency and brain development.

  2006cited by this paper
• MRI-determined regional brain iron concentrations in early- and late-onset restless legs syndrome.

  2006cited by this paper
• Presynaptic Control of Striatal Glutamatergic Neurotransmission by Adenosine A1–A2A Receptor Heteromers

  2006cited by this paper
• Cannabinoid Action Depends on Phosphorylation of Dopamine- and cAMP-Regulated Phosphoprotein of 32 kDa at the Protein Kinase A Site in Striatal Projection Neurons

  2005cited by this paper
• Regional and subtype selective changes of neurotransmitter receptor density in a rat transgenic for the Huntington's disease mutation

  2005cited by this paper
• Restless legs syndrome prevalence and impact: REST general population study.

  2005cited by this paper
• Interactions between Metabotropic Glutamate 5 and Adenosine A2A Receptors in Normal and Parkinsonian Mice

  2005cited by this paper
• Co‐localization and functional interaction between adenosine A2A and metabotropic group 5 receptors in glutamatergic nerve terminals of the rat striatum

  2005cited by this paper
• In vivo imaging of adenosine A2A receptors in rat and primate brain using [11C]SCH442416

  2005cited by this paper
• Dopamine and iron in the pathophysiology of restless legs syndrome (RLS).

  2004cited by this paper
• Decreased transferrin receptor expression by neuromelanin cells in restless legs syndrome

  2004cited by this paper
• Increased adenosine A2A receptors in the brain of Parkinson's disease patients with dyskinesias.

  2004cited by this paper
• Striatal plasticity at the network level. Focus on adenosine A2A and D2 interactions in models of Parkinson's Disease.

  2004cited by this paper
• Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease

  2004cited by this paper
• Adenosine A2A receptors are involved in physical dependence and place conditioning induced by THC

  2004cited by this paper
• Addicting drugs utilize a synergistic molecular mechanism in common requiring adenosine and Gi-βγ dimers

  2003cited by this paper
• Transgenic rat model of Huntington's disease.

  2003cited by this paper
• Metabotropic mGlu5 receptors regulate adenosine A2A receptor signaling

  2003cited by this paper
• Randomized trial of the adenosine A2A receptor antagonist istradefylline in advanced PD

  2003cited by this paper
• Iron status and neural functioning.

  2003cited by this paper
• Iron deficiency alters brain development and functioning.

  2003cited by this paper
• Aberrant A2A receptor function in peripheral blood cells in Huntington's disease

  2003cited by this paper
• Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology. A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health.

  2003cited by this paper
• Synergistic interaction between adenosine A2A and glutamate mGlu5 receptors: Implications for striatal neuronal function

  2002cited by this paper
• Twenty-four-hour motor activity in human infants with and without iron deficiency anemia.

  2002cited by this paper
• Increase of Preproenkephalin mRNA Levels in the Putamen of Parkinson Disease Patients with Levodopa‐Induced Dyskinesias

  2002cited by this paper
• Aggregated polyglutamine peptides delivered to nuclei are toxic to mammalian cells.

  2002cited by this paper
• The basal ganglia and disorders of movement: pathophysiological mechanisms.

  2002cited by this paper
• Coaggregation, Cointernalization, and Codesensitization of Adenosine A2A Receptors and Dopamine D2Receptors*

  2002cited by this paper
• Adenosine/dopamine interaction: implications for the treatment of Parkinson's disease.

  2001cited by this paper
• The Selective mGlu5 Receptor Agonist CHPG Inhibits Quinpirole-Induced Turning in 6-Hydroxydopamine-Lesioned Rats and Modulates the Binding Characteristics of Dopamine D2 Receptors in the Rat Striatum Interactions with Adenosine A2a Receptors

  2001cited by this paper
• The role of the D2 dopamine receptor (D2R) in A2A adenosine receptor (A2AR)-mediated behavioral and cellular responses as revealed by A2A and D2 receptor knockout mice

  2001cited by this paper
• Ultrastructural localization of adenosine A2A receptors suggests multiple cellular sites for modulation of GABAergic neurons in rat striatum

  2001cited by this paper
• Iron deficiency decreases dopamine D1 and D2 receptors in rat brain.

  2001cited by this paper
• The pattern of neurodegeneration in Huntington's disease: a comparative study of cannabinoid, dopamine, adenosine and GABA(A) receptor alterations in the human basal ganglia in Huntington's disease.

  2000cited by this paper
• Adenosine receptor expression and function in rat striatal cholinergic interneurons

  2000cited by this paper
• Huntington disease: new insights on the role of huntingtin cleavage.

  2000cited by this paper
• Alterations in preproenkephalin and adenosine‐2a receptor mRNA, but not preprotachykinin mRNA correlate with occurrence of dyskinesia in normal monkeys chronically treated with l‐DOPA

  2000cited by this paper
• Abnormalities in CSF concentrations of ferritin and transferrin in restless legs syndrome

  2000cited by this paper
• Iron deficiency alters dopamine transporter functioning in rat striatum.

  2000cited by this paper
• Dopamine-receptor stimulation: biobehavioral and biochemical consequences.

  2000cited by this paper
• Combined use of the adenosine A(2A) antagonist KW-6002 with L-DOPA or with selective D1 or D2 dopamine agonists increases antiparkinsonian activity but not dyskinesia in MPTP-treated monkeys.

  2000cited by this paper
• Reciprocal interactions between adenosine A2A and dopamine D2 receptors in Chinese hamster ovary cells co-transfected with the two receptors.

  1999cited by this paper
• Altered neurotransmitter receptor expression in transgenic mouse models of Huntington's disease.

  1999cited by this paper
• Motor system excitability in patients with restless legs syndrome

  1999cited by this paper
• Antiparkinsonian effect of a new selective adenosine A2A receptor antagonist in MPTP-treated monkeys

  1999cited by this paper
• Immunohistochemical localization of adenosine A2A receptors in the rat central nervous system

  1998cited by this paper
• In vivo dopamine metabolism is altered in iron-deficient anemic rats.

  1997cited by this paper
• Preproenkephalin mRNA expression in the caudate-putamen of MPTP monkeys after chronic treatment with the D2 agonist U91356A in continuous or intermittent mode of administration: comparison with L-DOPA therapy.

  1997cited by this paper
• Adenosine A2A receptor stimulation enhances striatal extracellular glutamate levels in rats.

  1995cited by this paper
• The subcellular distribution of [3H]-CGS 21680 binding sites in the rat striatum: copurification with cholinergic nerve terminals.

  1993cited by this paper
• Effects of adenosine A1 and A2 receptor activation on electrically evoked dopamine and acetylcholine release from rat striatal slices.

  1993cited by this paper
• Adenosine-dopamine interactions in the brain.

  1992cited by this paper
• Brain iron and dopamine receptor function.

  1983cited by this paper
• Iron deficiency during early development in the rat: behavioral and physiological consequences.

  1980cited by this paper
• The FASEB Journal express article 10.1096/fj.00-0730fje. Published online March 5, 2001. Aberrant amplification of A2A receptor signaling in striatal cells expressing mutant huntingtin

  year unknowncited by this paper

• Deletion of striatal adenosine A(2A) receptor spares latent inhibition and prepulse inhibition but impairs active avoidance learning.

  2013cites this paper